We invest in innovative private early- to mid-stage human Life Science companies that address important medical needs with novel technologies or products backed by compelling science and with differentiated advantages over current treatment options.
Our focus is on Switzerland and surrounding EU countries Germany, Austria, France, Italy and Benelux. We mostly invest in drug development and, to a lesser degree, in diagnostics and medical technology.
The amount we aim to invest over the lifetime of our portfolio companies is up to CHF 10 million. BioMedPartners often plays the lead or co-lead investor role structuring the transaction and syndicating with other venture capital firms.